SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

COLL

Collegium Pharmaceutical, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition is immediately accretive and extends Collegium's revenue runway with long patent protection. Watch for integration execution and prescription trends for AZSTARYS in upcoming quarters. The $300 million term loan increases leverage, but guided EBITDA of $475-$500 million provides strong coverage. Leadership departures are notable but appear orderly.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$35.69
T+0 close · May 12, 2026 · via day close
Latest settled
−18.44%
T+60 · $29.11
Vs SPY
−22.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $35.69entry
  2. T+1 · 6mo ago −2.30%α −2.87% · $34.87
  3. T+5 · 6mo ago −5.72%α −5.79% · $33.65
  4. T+20 · 5mo ago −2.49%α −0.77% · $34.80
  5. T+60 · 3mo ago −18.44%α −22.82% · $29.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 million in cash, funded by existing cash and a new term loan. The company raised its 2026 guidance to reflect the deal, now expecting product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million. The acquisition is expected to be immediately accretive and extends Collegium's revenue outlook with patent protection through 2037.

Key Financial Metrics

Guidance
$865M-$895M
raised
Deal Value
$650.0M

Key Facts

  • Acquired AZSTARYS for $650 million in cash, funded by $350 million cash on hand and $300 million from a delayed draw term loan.
  • Up to $135 million in additional milestone payments possible.
  • AZSTARYS generated over 760,000 prescriptions in 2025; expected to contribute $60-$70 million in net revenue in H2 2026.
  • 2026 guidance raised: product revenues $865-$895 million (from $805-$825 million); adjusted EBITDA $475-$500 million (from $455-$475 million).
  • Annual run-rate synergies expected to exceed $50 million within 12 months.
  • AZSTARYS has six Orange Book-listed patents, most expiring December 2037.
  • Two leadership departures: CCO Scott Dreyer (end of August 2026) and CMO Thomas Smith (transition period).

Financial Impact

$650 million upfront cash acquisition, plus up to $135 million in milestones; 2026 revenue guidance raised by $60-$70 million; EBITDA guidance raised by $20-$25 million.

revenueebitdadebtdilution

Risk Factors

  • Integration risk: realizing $50 million+ synergies within 12 months may be challenging.
  • Increased leverage from $300 million term loan; debt service costs could pressure margins.
  • AZSTARYS revenue guidance of $60-$70 million for H2 2026 may be optimistic if prescription growth slows.
  • Leadership departures of CCO and CMO could disrupt commercial and medical strategy.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292727

Track record

24 reports on COLL

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
  2. Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
  4. Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  6. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
  8. Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  9. Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  10. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026